Head-To-Head Analysis: Turnstone Biologics (NASDAQ:TSBX) vs. Inhibikase Therapeutics (NYSE:IKT)

Inhibikase Therapeutics (NYSE:IKT) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Inhibikase Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.

Insider and Institutional Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are owned by institutional investors. 4.6% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 32.1% of Turnstone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Inhibikase Therapeutics and Turnstone Biologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	605.57	-$19.03 million	($2.67)	-0.85
Turnstone Biologics	$19.31 million	0.52	-$55.20 million	($3.24)	-0.13

Inhibikase Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inhibikase Therapeutics and Turnstone Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-350.63%	-201.82%
Turnstone Biologics	N/A	-105.99%	-87.27%

Analyst Ratings

This is a summary of recent ratings and price targets for Inhibikase Therapeutics and Turnstone Biologics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	0	0	2	0	3.00
Turnstone Biologics	1	0	1	0	2.00

Inhibikase Therapeutics currently has a consensus target price of $6.50, indicating a potential upside of 186.34%. Turnstone Biologics has a consensus target price of $2.13, indicating a potential upside of 390.99%. Given Turnstone Biologics’ higher probable upside, analysts plainly believe Turnstone Biologics is more favorable than Inhibikase Therapeutics.

Summary

Turnstone Biologics beats Inhibikase Therapeutics on 8 of the 13 factors compared between the two stocks.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.